Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
Jun 27, 2024
|
Vigil Neuroscience to Present in Upcoming June Investor Conferences
May 30, 2024
|
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
May 08, 2024
|
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
|
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
Apr 17, 2024
|
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Mar 26, 2024
|
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
Mar 20, 2024
|
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
Mar 13, 2024
|
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
Mar 12, 2024
|
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
Mar 06, 2024
|
Displaying 1 - 10 of 13
Print Page
Email Alerts
RSS Feeds
Contact IR

Exit

You are leaving Vigil Neuroscience, Inc.’s website. You may return to Vigil Neuroscience, Inc.’s website by using the “Back” button on your Web browser toolbar or closing the window to the third-party website that you have opened. Do you wish to continue?